In a daily bulletin to clients on Friday, Tse maintained his “Sector Perform” rating while raising his target price from $6.00 to $7.00. (All figures in US dollars.)
Space technology company Maxar released its first quarter ended March 31, 2019, financials on May 9, coming in with revenue of $504-million versus Tse’s estimate of $458 million and Adjusted EBITDA of $117 million compared to Tse’s $96 million and margins improving from 17 per cent to 23 per cent.
Tse noted that Maxar’s order backlog shrank from $2.4 billion last quarter to $1.9 billion, which the analyst says suggests that the outlook for the remainder of the year will be challenged.
Maxar announced in January that it had sustained a fatal defect in its WorldView4 satellite, set to be the company’s primary money-maker in its Imagery segment. Since then, Maxar has stated that it will receive $183 million from insurance proceeds, yet Tse says that the money covers only “a fraction” of the potential value contribution lost and that debt remains a serious issue for the company.
“While Management has laid out another round of actions including further cost reduction and restructuring along with the insurance proceeds of $183 million from the failure of WorldView4, recent history suggests investors should stay clear until we see some steady execution,” says Tse.
The analyst is calling for 2019 revenue and EBITDA of $1.97-billion and $491 million, respectively, while his $7.00 target represented a projected return of six per cent at the time of publication.
ATB Capital Markets analyst Tim Monachello raised his rating on Questor Technology (Questor Technology Stock Quote, Chart, News, Analysts, Financials… [Read More]
Ventum Capital Markets analyst Amr Ezzat maintained a “Buy” rating and C$47.00 target price for Tecsys (Tecsys Stock Quote, Chart,… [Read More]
Roth Capital Markets analyst Scott Searle maintained a “Buy” rating and US$17.50 target price for Gogo (Gogo Stock Quote, Chart,… [Read More]
Research Capital analyst Andre Uddin maintained a “Speculative Buy” rating and C$12.00 target price on Eupraxia Pharmaceuticals (Eupraxia Pharmaceuticals Stock… [Read More]
Paradigm Capital analyst Marvin Wolff maintained a “Buy” rating and $0.55 target price for CHAR Technologies (CHAR Technologies Stock Quote,… [Read More]
Beacon Securities analyst Donangelo Volpe maintained a “Buy” rating and $2.00 target price for Imaflex (Imaflex Stock Quote, Chart, News,… [Read More]